Semaglutide linked to modestly lower cerebrovascular risk in meta-analysis of 27 trials

Semaglutide, the glucagon-like peptide-1 receptor agonist best known for its effects on blood sugar and body weight, may also modestly lower the risk of cerebrovascular events such as stroke-related conditions in people with type 2 diabetes or obesity, according to a new systematic review and meta-analysis published in Diabetology & Metabolic Syndrome. Pooling data from 27 randomized controlled trials involving 40,878 participants, the researchers found that patients taking semaglutide had a reduced risk of overall cerebrovascular events compared with those receiving other treatments, with a risk ratio of 0.88 and a 95% confidence interval of 0.78 to 1.00, reaching statistical significance at P = 0.045.

The analysis focused specifically on outcomes affecting the blood vessels of the brain, a domain where the evidence for semaglutide has been far less clear than for cardiovascular disease. While the drug has demonstrated favourable cardiovascular effects in previous research, whether that benefit extends to the brain’s vasculature remained uncertain. The study team set out to answer this question by systematically searching six major research databases—PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov—from their earliest records through September 23, 2025, using predefined semaglutide search terms.

To be included, trials had to test oral or subcutaneous semaglutide for at least 26 weeks in adults with type 2 diabetes mellitus or obesity. The researchers prespecified three cerebrovascular outcomes: ischemic stroke, hemorrhagic stroke, and transient ischemic attack, often called a TIA or ministroke. They pooled risk ratios using a random-effects model and conducted subgroup and sensitivity analyses to test the robustness of their findings. Risk of bias was evaluated with the RoB 2 tool, and the certainty of the evidence was graded using the GRADE framework.

Beyond the overall finding, the analysis revealed a numerically lower risk of transient ischemic attack among semaglutide users, with a risk ratio of 0.84 and a 95% confidence interval of 0.70 to 1.00 at P = 0.055. However, this result fell just short of the conventional threshold for statistical significance. The authors emphasized that because the 95% confidence intervals for both the overall cerebrovascular event estimate and the TIA estimate abutted the null value of 1.00, these borderline findings should be interpreted with caution.

No statistically significant associations were identified for ischemic cerebrovascular events or for hemorrhagic cerebrovascular events when analyzed separately. This means the apparent overall benefit did not clearly localize to one stroke subtype, leaving open the question of which specific cerebrovascular mechanisms, if any, drive the modest reduction in combined events.

The researchers also conducted prespecified exploratory subgroup analyses stratified by age, dose, and treatment duration. These showed a significantly reduced risk of transient ischemic attack among patients treated for 52 weeks or longer, with a risk ratio of 0.83 and a 95% confidence interval of 0.69 to 0.99 at P = 0.042, and among those without type 2 diabetes, with a risk ratio of 0.69 and a 95% confidence interval of 0.52 to 0.92 at P = 0.011. The authors stressed that these observed differences across treatment duration and diabetes status were exploratory and should be interpreted cautiously.

The primary findings held up in sensitivity analyses, suggesting they were not driven by any single trial or methodological choice. The GRADE assessment rated the certainty of the evidence as moderate, indicating reasonable confidence in the pooled estimates while acknowledging that further studies are needed to confirm the findings.

The study’s conclusion is measured rather than triumphant. The authors state that their findings suggest semaglutide may be associated with a lower risk of overall cerebrovascular events and transient ischemic attack in patients with type 2 diabetes or obesity, but they stop short of declaring a definitive protective effect. The borderline nature of the key results, with confidence intervals touching the null value, means the true effect size could plausibly be smaller than estimated or even absent.

For clinicians and patients, the analysis adds a cerebrovascular dimension to the ongoing evaluation of a widely used drug class, but it does not establish semaglutide as a proven stroke-prevention therapy. The evidence base consists of randomized controlled trials of at least 26 weeks’ duration in adults with type 2 diabetes or obesity, and the pooled results reflect those populations. Whether longer treatment durations, different doses, or populations beyond those studied would yield clearer cerebrovascular benefits remains an open question that the authors say requires further research to confirm.

Subject of Research: Cerebrovascular outcomes of semaglutide in patients with type 2 diabetes or obesity

Article Title: Cerebrovascular outcomes of semaglutide in patients with type 2 diabetes mellitus or obesity: a systematic review and meta-analysis

Article References: Lu, H.-L., Zhou, X.-Y., Wu, Q., Xie, J.-J., He, N.-X., Li, T., Xu, Y., Guo, M., & Teng, F.-Y. (2026). Cerebrovascular outcomes of semaglutide in patients with type 2 diabetes mellitus or obesity: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-026-02304-y

Image Credits: AI Generated

DOI: 10.1186/s13098-026-02304-y

Keywords: semaglutide, type 2 diabetes, obesity, stroke, transient ischemic attack, meta-analysis, systematic review, cerebrovascular disease, GLP-1 receptor agonist, randomized controlled trials, Cerebrovascular, outcomes